Erratum to Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review

Abstract

The standard errors of the natural log rate ratio (RR) were incorrectly input during the statistical process, leading to false-negative treatment results of interferon-beta (IFN-β) on annualized relapse rate ^[1]. The corrected statistical data showed that high-dose IFN-β significantly reduced annualized relapse rate at one year or two years of follow-up (RR = 0.690, 95%CI: 0.600-0.790, P = 0.000, Figure 4a, and RR = 0.680, 95%CI: 0.610-0.770, P = 0.000, Figure 4b, respectively).